Stagezero Life Sciences (TSE:SZLS) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
StageZero Life Sciences has announced a delay in filing its 2023 year-end and fourth-quarter financial results, citing lack of financial resources to fully pay for the audit process. The company expects its Q4 2023 revenue to align with previous quarters and has informed regulatory bodies while seeking a Management Cease Trade Order, which won’t affect non-insider trading. StageZero reassures there are no undisclosed material concerns or insolvency proceedings affecting the company.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.
